CD38 and Miyoshi myopathy: For example, daratumumab, a mAb targeting CD38 is being tested in multiple myeloma (MM) in combination with FT576, a B cell maturation antigen (BCMA) specific CAR NK with high-affinity, non-cleavable CD16, and a knockout of CD38 (to prevent fratricide) (NCT05182073).